Top

Taking a novel approach to drug development

Scroll Down

Taking a novel approach to drug development

Patents

Lantern Pharma’s drug development approach is innovative, using machine learning and A.I. to test and develop cancer treatments. From the novel small molecule compounds in our portfolio, to our targeted, rare patient populations who will benefit from these drugs, our pending and issued patent portfolio reflects our unique precision oncology focus.

Lantern Pharma actively manages a patent portfolio that includes over 80 issued patents and pending applications across 14 patent families. These patents stand as proof of our constant innovation using A.I. and machine learning to develop cancer treatments, and our focused dedication to the progress of oncology treatments.

Pending Patent Applications

SYSTEMS AND METHODS FOR IDENTIFYING CANCER TYPES AND SUBTYPES SUITABLE FOR TREATMENT WITH A DRUG CANDIDATE

General Application

RADR – Drug Discovery

Patent Summary

This is application is directed to method for identifying and stratifying drug treatments using subtypes identified using iterative process.

Countries

TBD

Priority Date

5/18/2020

GENE SIGNATURE OF RESPONSE TO AGENT TO IDENTIFY TUMOR INDICATIONS BASED ON MACHINE LEARNING TECHNIQUES AND METHODS OF USE THEREOF

General Application

RADR – Drug Discovery

Patent Summary

This is application is directed to method for identifying drug responsiveness using scoring of one or more binary mutations.

Countries

TBD

Priority Date

2/26/2021

ENSEMBLE METHOD WITH MACHINE LEARNING AND DEEP LEARNING FOR DRUG DISCOVERY

General Application

RADR – Drug Discovery

Patent Summary

This is application is directed to method for identifying drug responsiveness using scoring of one or more binary mutations.

Countries

TBD

Priority Date

3/10/2022

Method for Treating Cancer with Acylfulvene and Radiation

General Application

HydroxyUreaMethyl Acylfulvene

Patent Title

Method for Treating Cancer with Acylfulvene and Radiation

Patent Summary

This is application is directed to methods for treating Cancers by administration of HydroxyUreaMethyl Acylfulvene with radiation doses.

Countries

TBD

Priority Date

11/18/2021

Method for Treating Leukemia and Blood Cancers

General Application

HydroxyUreaMethyl Acylfulvene

Patent Title

Method for Treating Leukemia and Blood Cancers

Patent Summary

This is application is directed to methods for treating Leukemia and Blood Cancers by administration of HydroxyUreaMethyl Acylfulvene.

Countries

TBD

Priority Date

5/03/2021

Method for Treating Breast Cancers and PARP Resistant Breast Cancers

General Application

HydroxyUreaMethyl Acylfulvene

Patent Title

Method for Treating Breast Cancers and PARP Resistant Breast Cancers

Patent Summary

This is application is directed to methods for treating breast cancer and PARP resistant breast cancers by administration of HydroxyUreaMethyl Acylfulvene.

Countries

TBD

Priority Date

7/15/2022

Method for Treating Brain Metastases and CNS Metastases Using Illudins or HydroxyUreaMethyl Acylfulvene

General Application

HydroxyUreaMethyl Acylfulvene

Patent Title

Method for Treating Brain Metastases and CNS Metastases Using Illudins or HydroxyUreaMethyl Acylfulvene

Patent Summary

This is application is directed to methods for metastatic cancer by administration of HydroxyUreaMethyl Acylfulvene.

Countries

TBD

Priority Date

1/10/2021

Method for Treating Lung Cancer and Non-Small Cell Lung Cancer

General Application

HydroxyUreaMethyl Acylfulvene

Patent Title

Method for Treating Lung Cancer and Non-Small Cell Lung Cancer

Patent Summary

This is application is directed to methods for treating lung cancer and NSCLC by administration of HydroxyUreaMethyl Acylfulvene.

Countries

TBD

Priority Date

4/12/2021

Method for Treating Rhabdoid Tumors

General Application

HydroxyUreaMethyl Acylfulvene

Patent Title

Method for Treating Rhabdoid Tumors

Patent Summary

This is application is directed to methods for treating rhabdoid by administration of HydroxyUreaMethyl Acylfulvene.

Countries

TBD

Priority Date

12/29/2020

Method For Treating Blood Cancers

General Application

Positive HydroxyUreaMethyl Acylfulvene

Patent Title

Method For Treating Blood Cancers

Patent Summary

This is application is directed to methods for treating blood cancers by administration of (+)-HydroxyUreaMethyl Acylfulvene.

Countries

TBD

Priority Date

5/3/2021

Treating Cancers with Combinations of Spironolactone and Acylfulvenes

General Application

HydroxyUreaMethyl Acylfulvene

Patent Title

Treating Cancers with Combinations of Spironolactone and Acylfulvenes

Patent Summary

This is application is directed to methods for treating cancer by administration of HydroxyUreaMethyl Acylfulvene and spironolactone.

Countries

TBD

Priority Date

7/29/2021

Treating Cancers with Combinations of PARP Inhibitor and Acylfulvenes

General Application

HydroxyUreaMethyl Acylfulvene

Patent Title

Treating Cancers with Combinations of PARP Inhibitor and Acylfulvenes

Patent Summary

This is application is directed to methods for treating cancer by administration of HydroxyUreaMethyl Acylfulvene and one or more PARP inhibitor.

Countries

TBD

Priority Date

7/29/2021

Method for Treating Pancreatic Cancer

General Application

HydroxyUreaMethyl Acylfulvene

Patent Title

Method for Treating Pancreatic Cancer

Patent Summary

This is application is directed to methods for treating pancreatic cancer by administration of HydroxyUreaMethyl Acylfulvene.

Countries

TBD

Priority Date

5/08/2020

Method for Treating Brain Cancer

General Application

HydroxyUreaMethyl Acylfulvene

Patent Title

Method for Treating Brain Cancer

Patent Summary

This is application is directed to methods for treating brain tumor cancer (e.g., glioblastoma) by administration of HydroxyUreaMethyl Acylfulvene.

Countries

TBD

Priority Date

4/10/2020

Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds

General Application

Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)

Patent Title

Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds

Patent Summary

This application is directed to a method for (i) increasing patient survival time; (ii) promoting the arrest or retardation of tumor progression; (iii) concomitantly maintaining or increasing the quality of life in a cancer patient; and/or (iv) potentiating the cytotoxic/cytostatic effects of a chemotherapy agent or agents used to treat a patient suffering from cancer.

Patent No./Application No.

14675607 (Issue Fee Paid)

Countries

US

Priority Date

9/16/10

Anticancer Drug Sensitivity-Determining Markers

General Application

RADR Applications

Patent Title

Anticancer Drug Sensitivity-Determining Markers

Patent Summary

This application is directed to a marker for use in determination of the sensitivity of a cancer patient to an anti-cancer agent (e.g., illudins) to be administered thereto, which marker can determine whether or not the cancer of the patient has a therapeutic response to the anti-cancer agent, and to application of the marker.  Also included is a method for determining sensitivity of a subject having cancer to a illudin-based anti-cancer agent, the method includes measuring a level or presence of PTGR1 and at least one other gene.

Patent No./Application No.

PCT/US19/56039

Countries

US and other countries TBD

Priority of Filing Date

10/14/18

Illudin Analogs, Used Thereof, and Methods for Synthesizing the Same

General Application

Next Generation Illudins

Patent Title

Illudin Analogs, Used Thereof, and Methods for Synthesizing the Same

Patent Summary

This application is directed to illudin derivatives or analogs, intermediates, preparation methods, pharmaceutical compositions and uses thereof.  A new and potentially more potent illudin is disclosed in this application.

Patent No./Application No.

PCT/US19/49555

Countries

US and other countries TBD

Priority Date

9/4/18

Method for Treating Female Non-Smokers with Non-Small Cell Lung Cancer

General Application

Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)

Patent Title

Method for Treating Female Non Smokers with Non-Small Cell Lung Cancer

Patent Summary

This application is directed to a method for increasing survival time in a female patient with non-small cell lung carcinoma or non-small cell lung carcinoma in which 2,2′-dithio-bis-ethane sulfonate or salt is administered in a therapeutically effective amount to the patient with non-small cell lung carcinoma.

Patent No./Application No.

PCT/US20/21615

Countries

US and other countries TBD

Priority Date

3/8/19

PTGR1 Sensitivity and Acylfulvene Efficacy in Cancer Treatments

General Application

Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)

Patent Title

Method for Treating Female Non Smokers with Non-Small Cell Lung Cancer

Patent Summary

This application is directed to a method for increasing survival time in a female patient with non-small cell lung carcinoma or non-small cell lung carcinoma in which 2,2′-dithio-bis-ethane sulfonate or salt is administered in a therapeutically effective amount to the patient with non-small cell lung carcinoma.

Patent No./Application No.

PCT/US20/21615

Countries

US and other countries TBD

Priority Date

3/8/19

Contemporaneous, Multiple Protein-Targeted Therapeutic Modification and/or Modulation of Disease by Administration of Sulfur-Containing, Amino Acid-Specific Small Molecules

General Application

Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)

Patent Title

Contemporaneous, Multiple Protein-Targeted Therapeutic Modification and/or Modulation of Disease by Administration of Sulfur-Containing, Amino Acid-Specific Small Molecules

Patent Summary

This patent is directed to a method for the contemporaneous, heterogeneously-oriented metabolic modification and/or modulation of the expression level of multiple target molecules; wherein any combination of target molecules is selected from the group consisting of: anaplastic lymphoma kinase (ALK), mesenchymal epithelial transition (MET) kinase, the receptor tyrosine kinase (ROS1), epidermal growth factor receptor (EGFR), peroxiredoxin (Prx), excision repair cross-complementing protein 1 (ERCC1), insulin growth factor 1 receptor (IGF1R), ribonucleotide reductase, tubulin, farnesyltransferase, and other target molecules possessing a similar active site or structural motif.

Patent No./Application No.

14455855

Countries

US

Priority Date

8/8/14

Issued Patents

Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds

General Application

LP-300

Patent Title

Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds

Patent Summary

The patent is directed to increasing the survival time of cancer patients receiving LP-300 for cancers that are marked by overexpression of the regulatory proteins thioredoxin (TRX) or glutaredoxin (GRX) and/or exhibition of TRX- or GRX-mediated resistance to one or more chemotherapeutic interventions.

Patent No./Application No.

U.S. Patent No. 11,471,431

Countries

US Only

Priority Date

10/18/2022

Antitumor Agents

General Application

Irofulven

Patent Title

Antitumor Agents

Patent Summary

This application is directed to various acylfulvene analogs with various R groups thereon

Patent No./Application No.

US7141603

Countries

US Only

Priority Date

11/28/06

Illudin Analogs Useful as Anticancer Agents

General Application

Irofulven

Patent Title

Illudin Analogs Useful as Anticancer Agents

Patent Summary

This patent is directed to acylfulvene analogs, which inhibit tumor growth, especially solid tumor growth, and which have an adequate therapeutic index to be effective for in vivo treatment

Patent No./Application No.

US7655695

Countries

EP1909783B1 (Germany, France, and Great Britain), JP4989648 (US is Priority Application)

Priority Date

2/2/10

Compounds and Methods for Reducing Undesired Toxicity of Chemotherapeutic Agents

General Application

Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)

Patent Title

Compounds and Methods for Reducing Undesired Toxicity of Chemotherapeutic Agents

Patent Summary

This patent is directed to compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium.

Patent No./Application No.

US7176192

Countries

Australia

Priority Date

10/26/01

Anti-Cancer Activity Augmentation Compounds and Formulations & Methods of Use Thereof

General Application

Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)

Patent Title

Anti-Cancer Activity Augmentation Compounds and Formulations & Methods of Use Thereof

Patent Summary

This patent is directed to methods for augmentation of anti-cancer activity

Patent No./Application No.

China ZL200780017354

Countries

China, Australia

Priority Date

3/16/07

Method for Treating Cancer Having Greater Efficacy and Reduced Adverse Effects

General Application

Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)

Patent Title

Method for Treating Cancer Having Greater Efficacy and Reduced Adverse Effects

Patent Summary

This patent is direct to reducing side effects with  disulfide or thiol-containing compound .

Patent No./Application No.

US6596320

Countries

US

Priority Date

1/11/02

Process for Synthesizing Pharmaceutically Active Disulfide Salts

General Application

Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)

Patent Title

Process for Synthesizing Pharmaceutically Active Disulfide Salts

Patent Summary

This patent is directed to a process for synthesizing pharmaceutically active  disulfide or thiol-containing compound

Patent No./Application No.

US6504049

Countries

Australia, Canada, Denmark, France, Germany,  Ireland, Italy, Japan, Netherlands, Spain, Sweden, Switzerland, UK and US

Priority Date

5/30/02

Drugs for Prophylaxis or Mitigation of Taxane-Induced Neuropathies

General Application

Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)

Patent Title

Drugs for Prophylaxis or Mitigation of Taxane-Induced Neuropathies

Patent Summary

This Patent covering treating taxane neuropathy with 2,2_-dithiobis ethane sulfonate

Patent No./Application No.

US8710095

Countries

Australia,  France, Germany,  Japan, Spain, Sweden, Switzerland,  UK and US

Priority Date

4/30/02

Method For Preparing Disodium 2,2′-Dithiobis(Ethanesulfonate)

General Application

Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)

Patent Title

Method For Preparing Disodium 2,2′-Dithiobis(Ethanesulfonate)

Patent Summary

This patent is direct to a method for preparing Disodium 2,2′-Dithiobis(Ethanesulfonate)

Patent No./Application No.

US6936733

Countries

Australia, Belgium, France, Germany, Ireland, Italy, Japan, Sweden, Switzerland, UK and US

Priority Date

7/17/01

Compounds and Methods for Reducing Undesired Toxicity of Chemotherapeutic Agents

General Application

Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)

Patent Title

Compounds and Methods for Reducing Undesired Toxicity of Chemotherapeutic Agents

Patent Summary

The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium.

Patent No./Application No.

US Patent Nos. 7829540, 7829539, 7829117, 7829538 & 7235589

Countries

France, UK and US

Priority Date

11/14/07

Method of Treating Patients Undergoing Kidney Dialysis

General Application

Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)

Patent Title

Method of Treating Patients Undergoing Kidney Dialysis

Patent Summary

This invention relates to a method of treating patients who are receiving dialysis treatments. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.

Patent No./Application No.

US7235589

Countries

France, UK and US

Priority Date

9/21/05

Process for Synthesizing Disulfides

General Application

Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)

Patent Title

Process for Synthesizing Disulfides

Patent Summary

This patent discloses a process for producing a substantially pure disulfide , such as disodium 2,2_-dithiobis ethane sulfonate, by an efficient procedure from available, relatively inexpensive raw materials.

Patent No./Application No.

US7053240

Countries

Australia, Canada, China

Priority Date

12/17/04

Chemoprotective Methods and Compositions

General Application

Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)

Patent Title

Chemoprotective Methods and Compositions

Patent Summary

Compositions and methods for reducing, preventing, mitigating, and/or delaying the onset of, attenuating the severity of, and/or hastening the resolution of, for example, one or more chemotherapy-associated toxicities in a subject receiving one or more chemotherapeutic agents.

Patent No./Application No.

CA2648945

Countries

Australia, Canada, China, Denmark, France, Germany, Hungary, Ireland, Italy, Japan, Netherlands,  Sweden, Switzerland, and UK

Priority Date

12/13/06

Treatment Methods and Compositions for Lung Cancer, Adenocarcinoma, and Other Medical Conditions

General Application

Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)

Patent Title

Treatment Methods and Compositions for Lung Cancer, Adenocarcinoma, and Other Medical Conditions

Patent Summary

This patent is directed to an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions

Patent No./Application No.

US9320760

Countries

Australia, Canada, China, Denmark, France, Germany, Japan, Netherlands, Sweden, Switzerland, UK, and US

Priority Date

7/15/08

Medicinal Disulfide Salts

General Application

Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)

Patent Title

Medicinal Disulfide Salts

Patent Summary

This patent is directed to various medicinal disulfide salts

Patent No./Application No.

US7282602

Countries

Canada, Japan, Mexico, and US

Priority Date

9/21/04

Treatment Methods and Compositions for Lung Cancer, Adenocarcinoma, and Other Medical Conditions

General Application

Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)

Patent Title

Treatment Methods and Compositions for Lung Cancer, Adenocarcinoma, and Other Medical Conditions

Patent Summary

This patent is directed to an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions

Patent No./Application No.

US9320760

Countries

Australia, Canada, China, Denmark, France, Germany, Japan, Netherlands, Sweden, Switzerland, UK, and US

Priority Date

7/15/08

Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds

General Application

Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)

Patent Title

Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds

Patent Summary

This patent is directed to an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions

Patent No./Application No.

US9023805

Countries

US

Priority Date

9/16/10

"We are in the golden age of A.I. where we are able to significantly impact the speed and precision at which we develop new drugs."
Panna Sharma
PRESIDENT & CEO, LANTERN PHARMA

By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.